RiNA GmbH Acquires Roche RTS Protein Expression Portfolio
Roche and RiNA GmbH of Berlin have agreed to transfer the complete Roche Applied Science RTS protein expression portfolio to RiNA GmbH, effective September 15, 2009. RiNA will contribute its experience in the field of cell-free Expression systems and continue production at the same quality standards defined by Roche. Responsible for sales, support, and distribution of the RTS portfolio worldwide will be 5 PRIME GmbH of Hamburg, adding a global team of support, direct sales, and distributors. Both partners are committed to maintaining unchanged quality and price of RTS products.
“Roche Applied Science is focusing on innovative technologies in genomics, and we believe that a company specializing in proteomics will be able to develop the potential of RTS technology much faster than we can,” states Manfred Baier, Head of Roche Applied Science.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.